ArticleProceedings of the National Academy of Sciences of the United States of America2019
AWZ1066S, a highly specific anti-
Registry-linked trialOpen access · bronzeAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05084560 (Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug), which is not on this map. Cited by 39 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 2 pooled it
7.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Updated annotation and meta-analysis of Brugia malayi transcriptomics data reveals consistent transcriptional profiles across time and space with some study-specific differences in adult female worm transcriptional profiles.PLoS neglected tropical diseases · 2024Pooled it
- A Meta-Analysis ofG3 (Bethesda, Md.) · 2020Pooled it
- The history of Wolbachia and heartworm.Parasites & vectors · 2026Review
- Autophagy is essential for anti-Frontiers in microbiology · 2026Article
- Onchocerciasis overview: pathogenesis, clinical spectrum, and therapeutic challenges of a neglected tropical disease.Frontiers in parasitology · 2026Review
- Current perspectives in the epidemiology and control of lymphatic filariasis.Clinical microbiology reviews · 2025Review
- Differences of in vitro immune responses between patent and pre-patent Litomosoides sigmodontis-infected mice are independent of the filarial antigenic stimulus used.Parasitology research · 2024Article
- Targeting a microbiotaScience advances · 2024Article
- Combinations of the azaquinazoline anti-Frontiers in microbiology · 2024Article
- A diverse microbial community and common core microbiota associated with the gonad of female Parascaris spp.Parasitology research · 2023Article
- Multiple lineages of nematode-Wolbachia symbiosis in supergroup F and convergent loss of bacterioferritin in filarial Wolbachia.Genome biology and evolution · 2023Article
- Filariasis research - from basic research to drug development and novel diagnostics, over a decade of research at the Institute for Medical Microbiology, Immunology and Parasitology, Bonn, Germany.Frontiers in tropical diseases · 2023Article
- The pipeline for drugs for control and elimination of neglected tropical diseases: 1. Anti-infective drugs for regulatory registration.Parasites & vectors · 2023Review
- Dirofilariasis mouse models for heartworm preclinical research.Frontiers in microbiology · 2023Article
- The microbial community associated with Parascaris spp. infecting juvenile horses.Parasites & vectors · 2022Article
- A mouse infection model and long-term lymphatic endothelium co-culture system to evaluate drugs against adult Brugia malayi.PLoS neglected tropical diseases · 2022Article
- Article
- A qPCR to quantify Wolbachia from few Onchocerca volvulus microfilariae as a surrogate for adult worm histology in clinical trials of antiwolbachial drugs.Parasitology research · 2022Article
- Current perspective of new anti-Wolbachial and direct-acting macrofilaricidal drugs as treatment strategies for human filariasis.GMS infectious diseases · 2022Review
- The filarial and the antibiotics: Single or combination therapy using antibiotics for filariasis.Frontiers in cellular and infection microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 7 institutions in 4 countries.
W David HongDepartment of Chemistry, University of Liverpool, L69 7ZD Liverpool, United Kingdom.
Farid BenayoudEisai AiM Institute, Eisai, Inc., Andover, MA 01810.
Gemma L NixonDepartment of Chemistry, University of Liverpool, L69 7ZD Liverpool, United Kingdom.
Louise FordResearch Centre for Drugs and Diagnostics, Department of Parasitology, Liverpool School of Tropical Medicine, L3 5QA Liverpool, United Kingdom.ORCID 0000-0001-7919-2866
Kelly L JohnstonResearch Centre for Drugs and Diagnostics, Department of Parasitology, Liverpool School of Tropical Medicine, L3 5QA Liverpool, United Kingdom.
Rachel H ClareResearch Centre for Drugs and Diagnostics, Department of Parasitology, Liverpool School of Tropical Medicine, L3 5QA Liverpool, United Kingdom.ORCID 0000-0002-3945-0530
Andrew CassidyResearch Centre for Drugs and Diagnostics, Department of Parasitology, Liverpool School of Tropical Medicine, L3 5QA Liverpool, United Kingdom.
Darren A N CookResearch Centre for Drugs and Diagnostics, Department of Parasitology, Liverpool School of Tropical Medicine, L3 5QA Liverpool, United Kingdom.
Amy SiuEisai AiM Institute, Eisai, Inc., Andover, MA 01810.
Motohiro ShiotaniDrug Safety, Eisai Co., Ltd., 300-2635 Tsukuba, Japan.
Peter J H WebbornDrug Safety & Metabolism, IMED Biotech Unit, AstraZeneca UK, CB2 0AA Cambridge, United Kingdom.
Stefan KavanaghDrug Safety & Metabolism, IMED Biotech Unit, AstraZeneca UK, CB2 0AA Cambridge, United Kingdom.
Ghaith AljayyoussiResearch Centre for Drugs and Diagnostics, Department of Parasitology, Liverpool School of Tropical Medicine, L3 5QA Liverpool, United Kingdom.
Emma MurphyResearch Centre for Drugs and Diagnostics, Department of Parasitology, Liverpool School of Tropical Medicine, L3 5QA Liverpool, United Kingdom.
Andrew StevenResearch Centre for Drugs and Diagnostics, Department of Parasitology, Liverpool School of Tropical Medicine, L3 5QA Liverpool, United Kingdom.
John ArcherResearch Centre for Drugs and Diagnostics, Department of Parasitology, Liverpool School of Tropical Medicine, L3 5QA Liverpool, United Kingdom.
Dominique StrueverInstitute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, 53127 Bonn, Germany.
Stefan J FrohbergerInstitute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, 53127 Bonn, Germany.
Alexandra EhrensInstitute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, 53127 Bonn, Germany.
Marc P HübnerInstitute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, 53127 Bonn, Germany.
Achim HoeraufInstitute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, 53127 Bonn, Germany.
Adam P RobertsResearch Centre for Drugs and Diagnostics, Department of Parasitology, Liverpool School of Tropical Medicine, L3 5QA Liverpool, United Kingdom.
Alasdair T M HubbardResearch Centre for Drugs and Diagnostics, Department of Parasitology, Liverpool School of Tropical Medicine, L3 5QA Liverpool, United Kingdom.
Edward W TateDepartment of Chemistry, Imperial College London, SW7 2AZ London, United Kingdom.
Remigiusz A SerwaDepartment of Chemistry, Imperial College London, SW7 2AZ London, United Kingdom.ORCID 0000-0002-4684-3754
Suet C LeungDepartment of Chemistry, University of Liverpool, L69 7ZD Liverpool, United Kingdom.
Li QieDepartment of Chemistry, University of Liverpool, L69 7ZD Liverpool, United Kingdom.
Neil G BerryDepartment of Chemistry, University of Liverpool, L69 7ZD Liverpool, United Kingdom.
Fabian GusovskyEisai AiM Institute, Eisai, Inc., Andover, MA 01810.
Janet HemingwayDepartment of International Health, Liverpool School of Tropical Medicine, L3 5QA Liverpool, United Kingdom janet.hemingway@lstmed.ac.uk steve.ward@lstmed.ac.uk pmoneill@liverpool.ac.uk.
Joseph D TurnerResearch Centre for Drugs and Diagnostics, Department of Parasitology, Liverpool School of Tropical Medicine, L3 5QA Liverpool, United Kingdom.ORCID 0000-0002-2185-5476
Mark J TaylorResearch Centre for Drugs and Diagnostics, Department of Parasitology, Liverpool School of Tropical Medicine, L3 5QA Liverpool, United Kingdom.ORCID 0000-0003-3396-9275
Stephen A WardResearch Centre for Drugs and Diagnostics, Department of Parasitology, Liverpool School of Tropical Medicine, L3 5QA Liverpool, United Kingdom; janet.hemingway@lstmed.ac.uk steve.ward@lstmed.ac.uk pmoneill@liverpool.ac.uk.
Paul M O'NeillDepartment of Chemistry, University of Liverpool, L69 7ZD Liverpool, United Kingdom; janet.hemingway@lstmed.ac.uk steve.ward@lstmed.ac.uk pmoneill@liverpool.ac.uk.
Liverpool School of Tropical Medicine · GBUniversity of Liverpool · GBUniversity Hospital Bonn · DEEisai (United States) · USAstraZeneca (United Kingdom) · GBImperial College London · GBEisai (Japan) · JP
Funding
Medical Research Council MC_PC_16052Medical Research Council MC_PC_17167Medical Research Council MR/R025401/1
Abstract
Onchocerciasis and lymphatic filariasis are two neglected tropical diseases that together affect ∼157 million people and inflict severe disability. Both diseases are caused by parasitic filarial nematodes with elimination efforts constrained by the lack of a safe drug that can kill the adult filaria (macrofilaricide). Previous proof-of-concept human trials have demonstrated that depleting >90% of the essential nematode endosymbiont bacterium,
Indexed as
AnimalsAnti-Bacterial AgentsElephantiasis, FilarialFemaleMaleMiceMice, SCIDOnchocerciasisPyrimidinesQuinazolinesWolbachiaAnti-Bacterial AgentsPyrimidinesQuinazolinesthienopyrimidineanti-Wolbachiadrug discoverylymphatic filariasismacrofilaricideonchocerciasis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT05084560ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.